NRx Pharmaceuticals Applies for FDA Priority Voucher for NRX-100
Update: 2025-06-27
Description
NRx Pharmaceuticals, trading as NRXP on NASDAQ, has submitted an application for the FDA Commissioner’s National Priority Voucher for their IV Ketamine product, NRX-100. The company's focus on U.S.-based manufacturing and pursuit of a patent on their preservative-free process could enhance their competitive edge in treating suicidal depression and PTSD.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
